September 18, 2025 — Caesarea, Israel IceCure has been granted a Notice of Allowance by the U.S. Patent and Trademark Office for its next-generation XSense™ cryoprobe invention, a technological improvement in its cryoablation platform designed to enhance cryoprobe extraction, reduce tissue trauma, and improve the patient experience during minimally-invasive tumor freezing procedures.
Science Significance
The newly allowed patent covers a cryoprobe tip that integrates a heater, temperature sensor, and controlled gas pulses, enabling precise temperature management of the cryoprobe’s external surface—even while embedded in frozen tissue. This innovation is part of the XSense™ system, which builds on liquid-nitrogen-based cryoablation to destroy tumors by freezing them—a method beneficial for benign and cancerous lesions in organs like breast, kidney, lung, and liver.
Regulatory Significance
The Notice of Allowance indicates that the patent claim has passed substantive examination, positioning the technology for strong intellectual property protection in the U.S. regulatory ecosystem. The XSense™ System with cryoprobes has recently received regulatory approvals in both the United States and Israel, which supports adoption and commercialization in those markets.
Business Significance
Advertisement
This patent strengthens IceCure’s competitive edge in the MedTech oncology market by protecting a feature that may reduce procedural complications and operational costs. By enhancing the safety and efficiency of probe extraction, it may reduce cost of care and improve operating room workflows. The enhanced IP position may also improve valuation and attract partnerships or investment in expansion.
Patients’ Significance
For patients, the advanced cryoprobe design promises reduced risk of tissue injury during probe removal, potentially less pain, fewer complications, and quicker recovery. As procedures are minimally invasive and often outpatient, improvements in extraction methodology directly contribute to better patient safety and more comfortable experience.
Policy Significance
This development underscores the role of patent policy and regulatory approval in supporting innovation in medical devices. Policies that fast-track regulatory clearances for devices proven safe and effective, and that protect inventions via patents, help ensure medical advancements reach patients efficiently. This case reflects how patent allowance complements regulatory clearance to promote innovation and public health.
The Notice of Allowance for the XSense cryoprobe technology marks a significant step in tumor ablation innovation. With the patent protection in place and regulatory approvals secured in key markets, the next phase will likely involve wider clinical adoption and potential expansion into new indications. As the technology improves safety and efficiency, it may set a new benchmark for cryoablation procedures, improving outcomes for patients with tumors where freezing is a viable treatment option.
Source: IceCure Medical Press Release
